• Publications
  • Influence
MCL-1 as a Buffer for Proapoptotic BCL-2 Family Members during TRAIL-induced Apoptosis
Previous studies have suggested that Mcl-1, an antiapoptotic Bcl-2 homolog that does not exhibit appreciable affinity for the caspase 8-generated C-terminal Bid fragment (tBid), diminishesExpand
  • 105
  • 10
Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization
Interaction between the hydrophobic Bak BH3-binding groove and the BH3 domain of activator proteins is a key step in initiating Bak oligomerization and activation.
  • 125
  • 8
  • PDF
BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.
Follicular lymphoma (FL), an indolent neoplasm caused by a t(14;18) chromosomal translocation that juxtaposes the BCL2 gene and immunoglobulin locus, has a variable clinical course and frequentlyExpand
  • 73
  • 4
  • PDF
Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro.
The insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF1R) are receptor tyrosine kinases that participate in mitogenic and antiapoptotic signaling in normal and neoplastic epithelia.Expand
  • 47
  • 4
  • PDF
Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies.
The mammalian target of rapamycin (mTOR) plays crucial roles in proliferative and antiapoptotic signaling in lymphoid malignancies. Rapamycin analogs, which are allosteric mTOR complex 1 (mTORC1)Expand
  • 92
  • 3
4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.
The mammalian target of rapamycin (mTOR), a kinase that regulates proliferation and apoptosis, has been extensively evaluated as a therapeutic target in multiple malignancies. Rapamycin analogs,Expand
  • 37
  • 3
Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy.
Although treatment with the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) is known to protect a subset of cells from induction of apoptosis by death ligands such as FasExpand
  • 18
  • 3
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined
The farnesyltransferase inhibitor tipifarnib exhibits modest activity against acute myelogenous leukemia. To build on these results, we examined the effect of combining tipifarnib with other agents.Expand
  • 54
  • 2
Immunodetection of human topoisomerase I-DNA covalent complexes
A number of established and investigational anticancer drugs slow the religation step of DNA topoisomerase I (topo I). These agents induce cytotoxicity by stabilizing topo I-DNA covalent complexes,Expand
  • 25
  • 2
  • PDF
Performance of an oxidation ditch retrofitted with a membrane bioreactor during the start-up
The objective of this study is to elucidate the full-scale characteristics of an oxidation ditch (OD) retrofitted with a membrane bioreactor (MBR). Domestic wastewater entering an oxidation ditch atExpand
  • 13
  • 2